Hartline Investment Corp’s Humacyte HUMA Stock Holding History

Hartline Investment Corp’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-22,450	Closed	-$69.8K	–	249
2024 Q1	$69.8K	Buy	+22,450	New	+$75.5K	0.01%	401

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Hartline Investment Corp's HUMA Position: Q2 2024 in Review

Hartline Investment Corp sold out of Humacyte (HUMA) in Q2 2024, closing a stake of 22,450 shares — an estimated $69.8K sold.

Hartline Investment Corp first reported a position in HUMA in Q1 2024 and held it in 1 quarter. The position peaked at $69.8K in Q1 2024. 123 funds tracked by Wall St. Rank hold HUMA as of Q2 2024.

Hartline Investment Corp reported no remaining Humacyte position as of Q2 2024 after selling out during the quarter.
Hartline Investment Corp sold 22,450 Humacyte shares in Q2 2024, an estimated $69.8K.
Hartline Investment Corp first reported a position in Humacyte in Q1 2024 and held it in 1 quarter.
Hartline Investment Corp's Humacyte position peaked at $69.8K in Q1 2024.
123 funds tracked by Wall St. Rank held Humacyte as of Q2 2024.

Based on Hartline Investment Corp's 13F filing for Q2 2024, filed 9 Aug 2024.